Cullins are a family of evolutionarily conserved proteins that bind to the small RING finger protein, ROC1, to constitute potentially a large number of distinct E3 ubiquitin ligases. CUL7 mediates an essential function for mouse embryo development and has been linked with cell transformation by its physical association with the SV40 large T antigen. We report here that, like its closely related homolog PARC, CUL7 is localized predominantly in the cytoplasm and binds directly to p53. In contrast to PARC, however, CUL7, even when overexpressed, did not sequester p53 in the cytoplasm. We have identified a sequence in the N-terminal region of CUL7 that is highly conserved in PARC and a sequence spanning the tetramerization domain in p53 that are required for CUL7-p53 binding. CUL7 and MDM2 did not form a detectable tertiary complex with p53. In vitro, CUL7 caused only mono-or di-ubiquitination of p53 under the conditions MDM2 polyubiquitinated p53. Co-expression of CUL7 reduced the transactivating activity of p53. Constitutive ectopic expression of CUL7 increased the rate of cell proliferation and delayed UV-induced G2 accumulation in U2OS cells expressing functional p53, but had no detectable effect in p53-deficient H1299 cells. Deletion of the N-terminal domain of CUL7 or a mutation disrupting p53 binding abolished the ability of CUL7 to increase the rate of U2OS cell proliferation. Our results suggest that CUL7 functions to promote cell growth through, in part, antagonizing the function of p53.
Introduction
Protein ubiquitination typically involves a cascade of three distinct enzymatic activities to activate (E1), conjugate (E2) and ligate (E3) ubiquitin. A ubiquitin molecule can be ligated to a substrate either in a monomeric manner (monoubiquitination) to cause conformational change to the substrate or in a polyubiquitin chain which signals the substrate to be degraded by the 26S proteasome. Both ubiquitin activating and conjugating enzymes are well characterized and contain highly conserved functional domains. The identity and mechanism of E3 ubiquitin ligases, on the other hand, has been elusive and long postulated as an activity responsible for both recognizing substrates and for catalysing polyubiquitin chain formation (Hershko and Ciechanover, 1998) .
Currently, two major families of E3 ligases have been described. The HECT family of E3s contains a domain homologous to E6-associated protein (E6AP) carboxyl terminus that can form thioester linkages with ubiquitin Scheffner et al., 1995) . Multiple cellular proteins with diverse structures contain the HECT domain (five in budding yeast and B30 in human), implicating multiple substrates and physiological functions for the HECT family of E3 ligases (Pickart, 2001) . The RING family of E3s contains either an intrinsic RING finger domain or an associated RING subunit essential for their ubiquitin ligase activity (Joazeiro and Weissman, 2000) . The RING finger motif was initially defined a decade ago as a novel cysteinerich sequence present in several otherwise unrelated proteins (Freemont et al., 1991) . A large number of RING finger proteins are present in different eucaryotic organisms and are involved in various cellular processes (>350 in human genome). Ubiquitin ligase activity has been experimentally demonstrated for more than a dozen of them, and many more are believed to function as E3 ubiquitin ligases.
The cullin proteins assemble a unique and large family of ligases by binding to the small RING finger protein ROC1 (also known as RBX1, HRT1 and Sag1) (Deshaies, 1999) . There are three closely related cullin genes in both budding and fission yeast and six in worms, fruit flies and humans (Kipreos et al., 1996) . In addition, three proteins, PARC (Nikolaev et al., 2003) and CUL7 present in mammals (Dias et al., 2002) , and APC2 expressed in all eucaryotes (Yu et al., 1998; Zachariae et al., 1998) , contain significant sequence homology to cullins over an B180 amino-acid region involved in binding with ROC1 or a homologous small RING protein APC11, respectively. Genetic analyses in different organisms have linked various physiological functions with different cullin genes, ranging from cell cycle control, signal transduction, transcriptional regulation and maintenance of genomic integrity to organismal development. A possible explanation for such broad functions of cullins is that individual cullin proteins may assemble various distinct ligases to mediate the ubiquitination of multiple substrates, and thus carry out various functions in vivo.
Of three distantly related cullins, PARC and CUL7 share extensive sequence homology to each other (Dias et al., 2002; Nikolaev et al., 2003) . In addition to the cullin homology region which includes both the ROC1-binding site as well as sequences involved in NEDD8 conjugation, both proteins also contain a small region (110 residues) with limited sequence similarity (31% identity) to HERC2 (hect domain and rcc1 domain protein 2) within their N-terminal region, as well as a DOC (DOC1/APC10) domain. Additionally, PARC contains in its C-terminal region two RING fingers separated by a sequence in between the RING fingers (IBR), a unique sequence referred to as RING1-IBR-RING2 (RBR) that was also found in multiple proteins from many eukaryotic species (Marin et al., 2004) . The function of both PARC and CUL7 are poorly understood. Mice lacking Cul7 die around birth with respiratory stress and Cul7-null mouse embryos developed dermal and hypodermal hemorrhage (Arai et al., 2003) , implicating a critical function of CUL7 function in development.
The N-terminal region in cullins is mostly, if not entirely, responsible for substrate recruitment. Via its Nterminal domain, CUL1 binds with SKP1 and then an F-box protein to constitute SCF-ROC1 ligases (Bai et al., 1996; Feldman et al., 1997; Skowyra et al., 1997) , and CUL3 binds to BTB proteins to constitute distinct BTB-CUL3-ROC1 ligases (Furukawa et al., 2003; Geyer et al., 2003; Pintard et al., 2003; Xu et al., 2003) . A potential target of PARC function has been identified to be the tumor suppressor p53 (Nikolaev et al., 2003) , a sequence-specific transcription factor that acts in the nucleus to mediate various cellular stresses and is exported to the cytoplasm for ubiquitin-mediated degradation during normal cell growth (Ko and Prives, 1996; Levine, 1997; Zhang and Xiong, 2001a) . The PARC protein is localized predominantly in the cytoplasm and was reported to sequester p53 in the cytoplasm, leading to the notion that one function of PARC may be to negatively regulate p53 through cytoplasmic sequestration (Nikolaev et al., 2003) . Given the high degree of homology between PARC and CUL7, we carried out biochemical and functional analyses of CUL7, including investigating the possibility that CUL7, like PARC, may interact with and regulate the function of p53.
Results

CUL7 binds to ROC1 and possesses ubiquitin ligase activity
We previously mapped the ROC1-binding domain to approximately 100 amino-acid residues in CUL1 that are most conserved among all cullins, and are also highly conserved in CUL7, PARC and APC2 (Furukawa et al., 2000) . We determined whether CUL7, like other cullins, physically associates with ROC1 by a coupled transfection-co-immunoprecipitation assay. Cul7 is expressed at a very low to undetectable levels in most commonly used cell lines, making it more feasible to examine ectopically expressed CUL7. Epitope-tagged CUL7 and ROC1 were ectopically expressed singularly or in combination in cultured 293T cells. A specific CUL7-ROC1 association was readily detected (Figure 1a) . Our previous mutational analysis identified six amino acid residues in CUL1( 610 ILL-QYN 615 ) whose deletion substantially reduced CUL1-ROC1 binding (Furukawa et al., 2000) and are conserved in CUL7 ( 1472 LLLYLN 1477 ). Deletion of these six residues (CUL7
DROC1
) nearly abolished CUL7-ROC1 binding ( Figure 1a) . The lack of cell lines expressing detectable CUL7 prevent us from determining the formation and regulation of the endogenous CUL7-ROC1 complex at present. We transfected myc-tagged CUL7 into U2OS and 293T cells and isolated multiple independent CUL7 stable clones. CUL7 immunocomplexes derived from these stable cells exhibited high levels of auto-ubiquitin ligase activity which was abolished by the omission of either E1 or E2 (Figure 1b) . Together, these results suggest that CUL7, via its association with ROC1, may function as a ubiquitin ligase in vivo. Our results are consistent with the report that ectopically expressed CUL7 binds to ROC1 and forms an active ubiquitin ligase (Dias et al., 2002) .
CUL7 is cytoplasmically localized
In human cells, ROC1 and many cullins, including CUL1, CUL2, CUL4A and CUL5, are distributed in both the cytoplasmic and nuclear compartments. Nuclear import is linked with the neddylation and maturation of CUL1-dependent SCF ligases (Furukawa et al., 2000) . We determined the subcellular localization of CUL7 by indirect immunofluorescence and found that even when ectopically overexpressed, CUL7, like its closest related homologue PARC (Nikolaev et al., 2003) , localized predominantly in the cytoplasm (Figure 1c , and data not shown for other cell types). Treatment of cells with leptomycin B (LMB), an inhibitor of the Crm1-specific nuclear export pathway, accumulated p53 which is actively exported out of the nucleus and is degraded in the cytoplasm, but had no detectable effect on the cytoplasmic localization of CUL7 (Figure 1d ), indicating that CUL7, unlike its binding partner p53 (see below), is not actively shuttling between the nucleus and the cytoplasm.
Previous studies have demonstrated that disruption of ROC1 binding accumulated CUL1 in the cytoplasm, and conversely, overexpression of ROC1 promoted CUL1 nuclear localization, suggesting a role of ROC1 in facilitating CUL1 nuclear accumulation or retaining CUL1 in the nucleus (Furukawa et al., 2000) . To determine whether cytoplasmic localization of CUL7 CUL7 binds to p53 P Andrews et al was caused by an insufficient amount of ROC1 as a result of CUL7 overexpression, we determined if CUL7 subcellular localization was affected by ectopically overexpressed ROC1. CUL7 and ROC1 co-localization in the cytoplasm was evident in nearly all cells that were positively transfected by both plasmids and no significant nuclear accumulation of CUL7 was observed in these cells (Figure 1e ), suggesting that CUL7 may assemble a productive ligase complex with ROC1 and function in the cytoplasm. We also noted that ROC1 preferentially accumulated in the nucleus when it was singularly expressed and was localized mostly in the Subcellular localization of myc3-CUL7 was examined using indirect immunofluorescence. (d) CUL7 subcellular localization is not affected by leptomycin B (LMB) treatment. U2OS cells were transfected with CUL7, treated with LMB, fixed, and protein localization was determined using indirect immunoflourescence. (e) CUL7 is capable of forming a cytoplasmic ubiquitin ligase. U2OS cells were transfected with myc-Cul7 and ROC1. Myc-CUL7 and ROC1 subcellular localization was examined using the antibodies indicated.
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P Andrews et al cytoplasm when co-expressed with CUL7 (Figure 1e ), raising the possibility that at high levels, CUL7 may interfere with the function of other cullins by sequestering ROC1 in the cytoplasm.
CUL7 associates with p53 and SV40T antigen
To gain an initial view of the function of CUL7, we examined the CUL7 complex by coupled [ 35 S]metabolic labeling and immunoprecipitation ( 35 S-IP). To increase the specificity of detection, we constructed a double epitope-tagged CUL7 fused with two tandem copies of HA and three copies of FLAG at the N-and C-terminus of CUL7 (HA2-CUL7-FLAG3), respectively, and ectopically expressed it in various cell lines. A representative 35 S-IP analysis of CUL7 complexes is shown in Figure 2 . In addition to CUL7, several additional proteins were identified that appear to specifically associate with CUL7, as they were absent when the FLAG antibody was blocked by a molar excess of antigen peptide, suggesting that CUL7 may interact with multiple cellular proteins in vivo.
In 293T cells, at least five CUL7-interacting proteins were seen (pointed out by an arrow, compare lanes 5 and 6), including notably one at 53 kDa and one at 97 kDa that appear to correspond to p53 and SV40 large T antigen, respectively. A side-by-side comparison with both p53 and T antigen immunocomplexes supported the interpretation; both 53 and 97 kDa bands exhibited the same mobility as p53 and T antigen, and the 97 kDa band was not detected in the other three cell lines lacking T antigen. Reciprocally, a protein apparently corresponding to CUL7 was detected in p53 immunocomplexes derived from three cell lines expressing p53 (293, 293T and U2OS) but not in p53-deficient SaOS2 cells, and in T antigen immunocomplexes derived from 293T cells, but not the other three cell lines lacking T antigen. We carried out mass spectrometric analyses of CUL7 complexes derived from scaled up immunoprecipitations, and thus far have identified positively two proteins, the 97 kDa T antigen and 90 kDa heat-shock protein (HSP90, confirmatory data not shown). Mass spectrometric analysis of p53 was not conclusive, but a p53-CUL7 interaction was confirmed by direct IPWestern and mutagenesis analyses (see below). The level of 35 S-labelled (i.e. newly synthesized) CUL7 in complex with p53 was as high as in CUL7 complexes and substantially higher than that detected in the T antigen complex. The significance of this difference, whether resulting from a higher affinity of CUL7 to p53 than to the T antigen, and how these three proteins interact with each other has yet to be determined. The CUL7-T antigen interaction has been previously reported and our result confirms the finding (Tsai et al., 2000; Ali et al., 2004) .
Given their separate subcellular localization, one in the nucleus and one in the cytoplasm, we asked whether CUL7 and the T antigen, when co-expressed in the same cell, could relocalize each other. Myc-tagged CUL7 and an untagged T antigen were either singularly expressed or co-expressed in U2OS cells and their subcellular localization was determined by indirect immunofluorescence. As expected, CUL7 was localized predominantly in the cytoplasm and the T antigen was detected only in the nucleus (Figure 2b ) when expressed separately. When the two proteins were co-expressed, both retained their respective localization and no significant change of subcellular localization was seen for either protein.
These results are consistent with the relative low abundance of CUL7-T antigen association observed by co-immunoprecipitation (Figure 2a) , suggesting that the CUL7-T antigen interaction may be transient or involve only a small fraction of each protein. A similar pattern of interaction was also seen between CUL7 and p53 (see below).
CUL7 binds to p53
By transfection and coimmunoprecipitation assays, we demonstrated that CUL7 binds with p53 ( Figure 3a ). Mutation targeting the nuclear export signal (NES) in p53 (p53 DNES ) blocked p53 nuclear export and decreased CUL7-p53 association, whereas mutation targeting the nuclear localization signal (NLS) in p53 (p53 DNLS ) blocked p53 nuclear import and increased CUL7-p53 association ( Figure 3a ). These findings, taken together with the observation that CUL7 localizes predominantly in the cytoplasm and does not shuttle between the nucleus and the cytoplasm (Figure 1 ), are consistent with an interpretation that p53-CUL7 interaction occurs in the cytoplasm. We noticed, in this (lane 6) and other experiments, that overexpression of p53 consistently reduced the level of CUL7 protein. The molecular basis for this reduction is not clear.
An N-terminal domain of CUL7 mediates p53 binding
We generated a series of deletion mutants of CUL7 and mapped the site involved in p53 binding ( Figure 3b ). Deletion of the N-terminal 422 residues completely abolished CUL7's binding activity to p53 (Figure 3c ). The N-terminal 221 residues exhibited a low level of p53-binding activity and the N-terminal 965 residues exhibited a p53-binding activity that, when taking into consideration its lower level of expression, is close to the wild-type CUL7. We were unable to detect the expression of either CUL7 N422 or CUL7 N680 and suspected that both proteins might be unstable. Treatment of transfected cells with a proteasome inhibitor, MG132, prevented their rapid degradation and allowed us to examine their p53-binding activity. As shown in the right panel of Figure 3c , both CUL7 N422 and CUL7 N680 bind to p53 at a level close to that of wild-type CUL7.
To define the sequence in CUL7 required for p53 binding, we compared the N-terminal 422 residues of CUL7 with PARC and identified several highly conserved sequences for site-directed mutagenesis analysis. Deletion of an internal 16 residue, 389-404 in human CUL7 that is invariably conserved in mouse CUL7, in human PARC and contains only one amino-acid change in mouse PARC, completely abolished the p53-binding activity of CUL7 without any detectable effect on CUL7's binding with ROC1 ( Figure 3d ). Taken CUL7 binds to p53 P Andrews et al together, these results suggest that the N-terminal 422 residues of CUL7 are both required and sufficient for binding with p53. The N-terminal 422 amino-acid region of CUL7 is highly conserved with PARC (59% identical). Searches of current databases or pairwise comparison with known p53-binding proteins using this 35 S-labeled lysates were immunoprecipitated with the indicated antibodies and immunoprecipitates were resolved by SDS-PAGE followed by autoradiography. (b) U2OS cells were transfected with plasmids expressing the indicated protein and subcellular localization of myc3-CUL7 and the large T antigen was examined using indirect immunoflourescence.
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CUL7 binds to the tetramerization domain in p53
The p53 protein contains several well-characterized domains: a N-terminal domain (residues 1-100) contain- D389À404 were lysed and p53-CUL7 binding was determined by IP-Western analysis.
CUL7 binds to p53 P Andrews et al ing the transcriptional activation activity, an MDM2-binding sequence, several phosphorylation sites of DNA-damage-activated kinases and a nuclear export signal, a central domain (residues 100-300) responsible for sequence-specific DNA binding, and a C-terminal domain encompassing a tetramerization domain (residues 320-360), an NES (residues 339-352) and an extreme C-terminus (residues 363-393) containing most, if not all lysine residues for ubiquitination by MDM2 ligase (Ko and Prives, 1996; Levine, 1997; Zhang and Xiong, 2001a) (Figure 4a ). We generated a series of p53 deletion mutants, expressed in mammalian cells as GST fusion proteins, and tested their binding with wild-type CUL7 by a standard GST pull-down assay. An appreciable amount of CUL7 was precipitated from total cell extract with the GST-p53 fusion protein (Figure 4b ). Deletion of up to 200 residues (p53 DN100 and p53 DN200 ) from the N-terminus of p53 reduced somewhat, but did not abolish CUL7 biding, and a further deletion of another 100 residues (p53 DN300 ) completely abolished p53's binding activity with CUL7. Together with the finding that deletion of the extreme C-terminal 30 residues did not disrupt CUL7-p53 binding (see below), these results indicate that the N-terminal domain and an intact central domain is not required for p53 to bind with CUL7, and that CUL7 likely binds to a sequence between residues 200 and 360 in p53 spanning the tetramerization domain.
CUL7, p53 and MDM2 do not form a ternary complex Mapping of CUL7-binding site to a sequence between residues 200 and 360 suggests that CUL7-binding site is different from that of MDM2. Various specific mutations in the N-terminal region of p53 have been previously characterized that disrupt MDM2-p53 binding, including Leu14Gln/Phe19Ser and Leu22Gln/ Trp23Ser (Lin et al., 1994) , as well as DN25 and DN15. None of these mutants affected p53's binding with CUL7 (Figure 5a) , further supporting the notion that MDM2 and CUL7 bind to two separate sequences in p53. These data also suggest that binding of CUL7 with p53 does not require MDM2 and is not dependent on MDM2-mediated p53 ubiquitination.
This finding led us to determine whether these three proteins could form a CUL7-p53-MDM2 ternary complex bridged by p53. We examined the presence of MDM2 and p53 in CUL7 immunocomplexes in cells triply transfected with plasmids expressing all three proteins. Under the condition where a binary p53-CUL7 complex was readily demonstrated, no CUL7-MDM2 interaction was detected (Figure 5b ). The interpretation of whether CUL7 and MDM2 could simultaneously bind to p53 is, however, complicated by the fact that MDM2 promotes rapid p53 degradation. As a result, an MDM2-p53-CUL7 ternary complex could have formed, but existed in vivo only transiently and escaped detection by the co-immunoprecipitation assay. To rule out this possibility, we repeated the same experiment with a mutant MDM2 containing a point mutation in the RING finger (C464A) that completely abolished the ligase activity of MDM2. In reciprocal IPWestern analyses, p53 was readily detected in both CUL7 and MDM2 immunocomplexes, but neither CUL7 nor MDM2 was detected in the other immunocomplex (Figure 5c ). From these results, we conclude that CUL7-p53-MDM2 ternary complex, if assembled in vivo, present only in a very low level. There could be two possible explanations for this. Either p53 does not have sufficient surface areas to interact with two large proteins, CUL7 (185 kDa) and MDM2 (75 kDa) at the same time, or there was only a very small amount of p53 and Mdm2 proteins, both predominantly localized in the nucleus, present in the cytoplasm at the same time, making the detection of MDM2-p53-CUL7 ternary complex very difficult.
CUL7 is unable to promote p53 polyubiquitination in vitro To elucidate the functional consequences of the p53-CUL7 interaction, we first determined whether CUL7 promotes p53 polyubiquitination by both in vitro and in vivo ubiquitination assays. To avoid the possibility of 
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P Andrews et al transcriptional upregulation of MDM2 by p53, and to avoid a contaminating contribution of endogenous MDM2 ligase activity, we co-transfected CUL7 with a transcriptionally inactive p53 mutant (p53R273H) into p53-deficient H1299 cells. CUL7-p53 complexes, and control MDM2-p53 complexes, were immunoprecipitated and assayed in vitro for p53 ubiquitination after incubating with E1 and E2-Ubc5. Expression of CUL7 and MDM2 was confirmed by direct immunoblotting.
Under this assay condition, MDM2 promoted an efficient poly-or multiple ubiquitination of p53 (Figure 6a ). Under the same assay conditions, we readily detected ubiquitination of p53 by CUL7. Omitting E1 and E2 abolished p53 ubiquitination, excluding the possibility that observed p53 ubiquitination resulted from contamination of the CUL7 immunoprecipitates with ubiquitinated p53 generated in vivo. In repeated assays, we reproducibly detected CUL7 binds to p53 P Andrews et al predominantly p53 conjugated with one or two ubiquitin moieties. The significance of this difference between MDM2 and CUL7-promoted p53 ubiquitinationwhether it reflects a factor required for CUL7-mediated p53 polyubiquitination that is missing in this setting, or CUL7 and MDM2 are mechanistically different ligaseshas not been determined. Surprisingly, deletion of the cullin homology and ROC1-binding sequence, from residues 1472 to 1510, did not affect CUL7-mediated p53 ubiquitination (Figure 6a, lane 6) , suggesting that ROC1 binding is not essential for CUL7-mediated in vitro ubiquitination of p53. The nature of the CUL7-associated p53 ligase is not clear at present. One possible candidate ligase is APC11, which has been reported to bind tightly and stoichiometrically to APC10 (Tang et al., 2001) . CUL7, as well as PARC, contain a DOC domain highly related to APC10 (31% identical over 116 residues) and could, at least in theory, interact with APC11 and recruit ubiquitin ligase activity.
The observation that CUL7 can only promote monoor di-ubiquitination of p53 in vitro led us to examine the possibility that in vivo CUL7 may function in p53 ubiquitination and degradation through a collaboration with MDM2 in a sequential manner: p53 is first ubiquitinated by MDM2 in the nucleus and then the ubiquitin chain is elongated by CUL7, either alone, or in combination with MDM2, in the cytoplasm. The p53 protein was ectopically expressed in U2OS cells with various combinations and amounts of MDM2 and CUL7 as well as HA-ubiquitin. At 24 h post transfection, cells were treated with the proteasome inhibitor MG132 for 4 h to accumulate and to prevent degradation of ubiquitinated proteins. Cells were directly lysed with 1% SDS buffer and immediately boiled for 10 min. Diluted lysates were then immunoprecipitated with a p53 antibody, resolved by SDS-PAGE and immunoblotted with anti-HA to visualize ubiquitinated p53. Under the assay conditions where MDM2 promoted Figure 6 CUL7 promotes p53 mono-or di-ubiquitination but not p53 degradation. (a) The transcriptionally impaired p53R273H was co-transfected into p53-deficient H1299 cells with CUL7 or MDM2. CUL7-p53 and MDM2-p53 complexes were precipitated using either anti-myc (9E10) or anti-MDM2 (SMP14) antibodies. In vitro p53 ubiquitination assays were performed. Reactions were terminated by boiling in SDS sample buffer, resolved by SDS-PAGE and blotted with an anti-p53 antibody (DO1). (b) U2OS cells were co-transfected with plasmids expressing 6x (HA-Ub) and additional indicated proteins. Cells were pelleted, lysed with SDS buffer, and boiled for 10 min. Lysates were diluted 10-fold with 0.1% NP40 buffer and immunoprecipitated with a p53 antibody. Immunoprecipitates were resolved by SDS-PAGE and ubiquitinated p53 was visualized by Western blotting with an HA antibody (12CA5). (c) U2OS and U2OS cells constitutively expressing CUL7 were treated with cycloheximide to prevent protein synthesis. Total cell extracts were prepared at the indicated time points, and resolved by SDS-PAGE. The level of p53 and CUL7 was determined by direct Western blotting.
P Andrews et al efficient p53 ubiquitination, CUL7 alone was not able to promote ubiquitination of p53 in vivo (Figure 6b ). When co-expressed with MDM2, CUL7 did not exhibit any appreciable enhancing effect in promoting MDM2-dependent p53 polyubiquitination.
CUL7 does not affect the half-life of the p53 protein
We next determined the half-life of the p53 protein in response to CUL7 overexpression. Parental U2OS cells and U2OS cells stably expressing CUL7 were treated with cycloheximide to block new protein synthesis. Protein extracts were prepared at different time points after cycloheximide treatment and the steady-state level of p53 was determined by direct immunoblotting. The half-life of the p53 protein in logarithmically growing (i.e. unstressed) U2OS cells is approximately 30 min, and was not significantly affected by the ectopic overexpression of CUL7 (Figure 6c ). The inability of CUL7 to accelerate p53 degradation is consistent with its inability to promote p53 polyubiquitination.
CUL7 does not sequester p53 in the cytoplasm PARC, like CUL7, localized predominantly in the cytoplasm and was reported to inhibit p53 function via a cytoplasmic sequestration (Nikolaev et al., 2003) . Binding of p53 led us to test whether CUL7 similarly sequesters p53 in the cytoplasm. We examined p53 localization by indirect immunofluorescence in both U2OS cells and U2OS cells stably expressing CUL7. No obvious difference of p53 subcellular localization was detected ( Figure 7) . To increase the sensitivity of detection to confirm this finding, we ectopically expressed additional p53 in both parental U2OS and CUL7-overexpressing cells and determined p53 localization. Again, no obvious difference was seen in p53 nuclear and cytoplasmic distribution by the overexpression of CUL7 (Figure 7 ).
CUL7 represses the transcriptional activation activity of p53 and increased the rate of cell proliferation Using a luciferase reporter assay, we examined the CUL7 effects on basal p53 transcriptional activation utilizing a p21 promoter reporter construct. We found that CUL7, when co-transfected with p53, decreased the transcriptional activation activity of p53 (Figure 8a ). These results are consistent with an inhibitory activity of CUL7 toward p53.
To assess the function of CUL7 in controlling cell growth, we determined the effect of ectopic expression of CUL7 on cell proliferation in p53-positive U2OS cells and the requirement of p53-binding activity on this effect. We first established cell lines stably expressing CUL7 after transfection of U2OS cells and subsequent selection of G418-resistant clones and compared the rate of cell proliferation with parental U2OS cells. Constitutive expression of high levels of CUL7 from the CMV promoter resulted in an increased rate of proliferation of U2OS cells, indicating a role of CUL7 in promoting cell growth (Figure 8b ). To confirm this result and assess the requirement of p53 binding for this activity of CUL7, we generated three different retroviruses that express the wild-type CUL7 and two CUL7 mutants, one with a deletion of the N-terminal 680 amino-acid residues (referred to as CUL7
DN680
) containing all the p53-binding activity, and one deleting residues 389-404, which are required for p53 binding (CUL7
D389À404
). U2OS cells were transduced individually by each of the three viruses, stable pools were generated and the growth curve of each pool was determined (Figure 8c ). The expression of each protein was confirmed by direct immunoblotting. As seen with high level CUL7 Figure 7 CUL7 does not sequester p53 in the cytoplasm. U2OS cells were transfected with either CUL7, p53 or both and protein localization was examined using indirect immunofluorescence.
CUL7 binds to p53 P Andrews et al Figure 8 CUL7 promotes cell proliferation and antagonizes p53 function. (a) CUL7 represses the transactivating function of p53. A synthetic luciferase reporter containing 13 tandem copies of a p53 response element (pG13-Luc, El-Deiry et al., 1992) was either singularly transfected or in combination with plasmids expressing p53 and CUL7 into U2OS cells. Relative luciferase activity was calculated as described in Materials and methods. Error bars indicate standard deviation. CUL7 repression was determined to be significant by a Student's t-test, with P ¼ 2.8E-5. (b) A stable clone was isolated from U2OS cells after transfection of pcDNA3-myc3-CUL7 and subsequent selection of G418 resistance. The growth curves of parental U2OS and U2OS/CUL7 cells were determined. Relative proliferation was determined by dividing the cell number counted each day by the cell number counted on day 1. (c) U2OS cells were transduced with retroviruses expressing CUL7, CUL7 DN680 or CUL7 D389À404 . Stable pools of each transduction were plated in 60 mm dishes and the rate of cell proliferation was determined by counting cells daily and dividing the number of cells by the number of cells counted on day 1. Inset: protein expression of each retrovirally infected cell pool expressing CUL7, CUL7 DN680 or CUL7 D389À404 was determined by Western blot analysis. (d) H1299 cells were transduced with retroviruses expressing CUL7or CUL7
. Stable pools of each transduction were plated in 60 mm dishes and the rate of cell proliferation was determined by counting cells daily and divided by the number of cells on day 1. Inset: protein expression of each retrovirally infected cell pool was determined by Western blot analysis. (e) UV irradiated (40 J/M 2 ) parental and CUL7-expressing U2OS cells were collected at 0, 24 and 48 h and analysed by FACS.
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P Andrews et al expression in stable cell lines, retrovirally mediated constitutive expression of CUL7 increased the rate of cell proliferation over the course of the experimentation. Deletion of the N-terminal p53-binding domain or mutation of a sequence required for p53 binding both abolished the ability of CUL7 to promote cellular proliferation. To further correlate the changes in proliferation rate by ectopic CUL7 expression with p53 function, we similarly transduced wild-type and D389-404 mutant CUL7 retrovirus into p53-deficient H1299 cells. Unlike p53-positive U2OS cells, CUL7 expression in H1299 cells had no significant effect on the rate of cell proliferation (Figure 8d ).
CUL7 expression delayed UV-induced G2 accumulation
Following UV irradiation, p53-positive U2OS cells, but not p53-deficient H1299 cells, undergo a G2 arrest before resuming cell proliferation. While non-irradiated parental U2OS and H1299 cells exhibited similar cell cycle phasing, 43 and 63% of the parental U2OS cells accumulated in G2 phase 24 and 48 h after UV irradiation, respectively, and there is no significant G2 accumulation seen in H1299 cells (Figure 8e) . A G1 accumulation seen at the 48 h time point in H1299 cells might have been caused in part by the increase of cell density. The reason why U2OS cells accumulate in G2, as opposed to G1 seen in other cell types, is not clear at present and MAPKAP kinase 2 has been suggested to be a component of this UV-activated G2/M checkpoint in U2OS cells (Manke et al., 2005) . Non-irradiated CUL7-expressing U2OS cells exhibited a similar cell cycle distribution to parental U2OS cells, but CUL7-expressing U2OS cells displayed a increased G1 population and a delayed G2 accumulation after exposure to UV radiation; while 20 and 43% of the U2OS cells accumulated in G1 and G2 phase 24 h after UV irradiation, there was an increase of G1 population to 31% and no significant G2 accumulation seen in CUL7-expressing U2OS cells. At 48 h after irradiation, 63% of the U2OS cells accumulated in G2 with only 17% cells at G1, compared with 56% of the CUL7-expressing cells and 22% in G1. There was no significant change in the sub-G1 population (data not shown), suggesting that Cul7 expression did not interfere with p53's activity in promoting apoptosis following UV. The level of p21 CDK inhibitor protein was increased in CUL7-expressing U2OS (Figure 8e ). Given the function of CUL7 in repressing p53-dependent transcription, the increase of p21 is likely caused by a p53-independent mechanism. There was little difference between H1299 and CUL7-expressing H1299 cells in their response to UV irradiation (Figure 8e ). We therefore conclude that ectopic expression of CUL7 interferes with the cellular response to UV-generated DNA damage, likely by impairing the function of p53.
Discussion
In this report, we carried out a series of experiments aimed at gaining insight into the cellular function of CUL7. The major findings of the study are that CUL7, like its closely related protein, PARC, binds to ROC1, possesses ubiquitin ligase activity, localizes predominantly in the cytoplasm, and perhaps most significantly, interacts with p53. The tumor suppressor p53 acts as a sequence-specific transcription factor in the nucleus. Studies over the past several years have demonstrated that nuclear export and subcellular localization are critical regulatory events in p53 control (Zhang and Xiong, 2001a; Chipuk and Green, 2004) . Blocking p53 nuclear export inhibited MDM2-mediated p53 degradation and led to p53 stabilization (Roth et al., 1998; Tao and Levine, 1999; O'Keefe et al., 2003) , indicating that either p53 degradation occurs in the cytoplasm or requires a cytoplasmic factor(s). Potentially equally important as, and possibly linked with, the cytoplasmic degradation of p53 is the emerging mitochondrial role for p53 in promoting nuclear-and transcriptionindependent apoptosis (Baptiste and Prives, 2004; Chipuk and Green, 2004) . Very little is known about the regulation of cytoplasmic p53, including both newly synthesized and exported, stability, modification, subcytoplasmic localization, interacting partners and complex formation. Our studies suggest that CUL7, alongside its homologue PARC, may function as a cytoplasmic regulator of p53. Ectopic expression of CUL7 reduced p53's transactivating activity, increased the rate of cell proliferation, and delayed cellular response to DNA damage. Disruption of p53 binding abolished the ability of CUL7 to promote cell proliferation and to repress p53-mediated transcription. Targeted disruption of the mouse Cul7 gene resulted in retarded proliferation of mouse embryo fibroblasts (MEFs) and death of embryos soon after birth (Arai et al., 2003) . Together, these results demonstrate a growth-promoting function of CUL7. We further suggest that the growth promoting activity of CUL7 is attributed to, if not depends on, its ability to bind with p53 and that increased p53 activity could account for, at least in part, for the retarded proliferation of Cul7-null MEFs.
CUL7 has also been reported to bind with the SV40 large T antigen and deletion of a sequence from the T antigen that disrupt its binding with CUL7 abolished the ability of the T antigen to transform primary cells and to promote anchorage-independent cell proliferation (Ali et al., 2004) . Of the various cellular proteins that interact with the T antigen, two major ones -tumor suppressors p53 and the Rb family of proteins -are functionally inactivated, underlying the transforming activity of the T antigen (Ali and DeCaprio, 2001 ). The results generated thus far have not allowed us to build a simple model that could reconcile two seemingly distinct functions of CUL7: promoting cell growth through its p53-binding ability, and being a cellular target of T antigen-mediated cell transformation. Binding of CUL7 with p53 apparently does not require the T antigen. It, however, remains possible that the T antigen and CUL7 may facilitate one another's activity to cause functional inactivation of p53. A still puzzling issue is when and how CUL7, a cytoplasmic protein, binds to the T antigen and p53, both of which are localized predominantly in the nucleus. As determined by indirect immunofluorescence, we have not observed a significant change in the respective cytoplasmic and nuclear localization of CUL7 and p53 or CUL7 and the T antigen when the two proteins were co-expressed in the same cell.
The exact biochemical mechanism of CUL7, in particular how it affects p53, remains to be determined. It is surprising to see that, in contrast to PARC which has been reported to bind with p53 and sequester it in the cytoplasm (Nikolaev et al., 2003) , we have not been able to detect any cytoplasmic sequestration activity of CUL7 toward p53. In nearly all the cells that we have examined, p53, whether expressed at a low level endogenously or at a high level ectopically, remained localized predominantly in the nucleus despite ectopic expression of CUL7 (Figure 7 ). There were clear separations of p53 and CUL7 localization in cells expressing both proteins. The basis underlying the mechanistic difference between CUL7 and PARC in affecting p53 subcellular localization is not clear at present and requires further studies. We suspect that separate localization, rather than relocalizing each other, may explain the facts that CUL7-mediated repression of p53's transcription activity is incomplete, and that ectopic CUL7 expression caused only a delay, but not complete abrogation, of p53-mediated G2 arrest after UV irradiation.
Under the conditions where MDM2 can cause p53 polyubiquitination in vitro and p53 degradation in vivo, we were not be able to detect a similar function for CUL7 ( Figure 6 ). Instead, we have repeatedly observed a mono-and di-ubiquitination of p53 in vitro by CUL7. In co-transfection assays involving both CUL7 and MDM2, we have thus far not detected any enhancing effect by CUL7 on the ability of MDM2 to degrade p53 (data not shown). From these results, we cautiously conclude that CUL7 is unlikely to act as a p53 inhibitor by promoting p53 degradation and does not appear to be the long-sought cytoplasmic ubiquitin ligase responsible for p53 degradation. Instead, CUL7 may regulate p53 through non-proteolytic ubiquitination.
Materials and methods
Plasmids
Full-length human CUL7 cDNA was obtained from the Kazusa Gene project (KIAA0076), and subcloned into pcDNA3 mammalian expression vector with various epitope tags. Human p53, HDM2 (human homologue of MDM2) and ARF expression vectors were previously described (Zhang et al., 1998; Zhang and Xiong, 2001b) . GST-p53 and derivative deletion mutants were subcloned into the pEBG mammalian GST expression vector. Mutations were introduced by sitedirected mutagenesis using a Quick-Change site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) and verified by DNA sequencing.
Cell lines, cell culture and cell transfection Human U2OS cells used in this study were cultured in DMEM, supplemented with 10% FBS in a 371C incubator with 5% CO2. Cell transfections were carried out using FuGene (Roche, Alameda, CA, USA) or Effectene (Qiagen, Valencia, CA, USA) transfection reagents according to the manufacturer's instructions. For each transfection, final concentration of total plasmid DNA was normalized with pcDNA3 to 1, 4 or 7 mg for each six-well, 60 mm or 100 mm dish, respectively. To establish Cul7 stable expressing cell lines, U2OS cells were transfected with pcDNA3-myc3-Cul7. At 24 h after transfection, cells were trypsinized and re-seeded in a 1:10 000 dilution in media containing 0.75 mg/ml geneticin (Gibco (Invitrogen), Carlsbad, CA, USA) for 7 days. Twentyfour independent single colonies were selected and expression of CUL7 was analysed by direct immunoblotting using the anti-myc antibody.
Antibodies, immunochemistry and indirect immunofluorescence
Procedures for immunoprecipitation and immunoblotting have been described previously (Jenkins and Xiong, 1995) . Indirect immunofluorescence was previously described in detail (Zhang and Xiong, 2001b In vitro and in vivo ubiquitin ligase activity assays The procedure for in vitro assay of ubiquitin ligase activity was essentially the same as previously described (Ohta et al., 1999; Furukawa et al., 2002) . Purified rabbit E1 ubiquitin-activating enzyme was purchased from Affiniti Research Products (Exeter, UK). His-tagged E2 human UbcH5C was purified using nickel beads (QIAGEN). Ub was prepared by subcloning full-length Ub as a fusion protein with a 6x His-tag and protein kinase C recognition site (LRRASV) and purified with nickel beads (Tan et al., 1999) . Briefly, for both in vitro autoubiquitination (E2 activation) and p53 ubiquitination assays by the Cul7 ligase, wild-type or mutant CUL7 immunocomplexes were immunoprecipitated from transfected cells. Immunocomplexes immobilized on protein A agarose beads were washed and added to a Ub ligation reaction mixture (30 ml) that contained 50 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 2 mM NaF, 10 nM okadaic acid, 2 mM ATP, 0.6 mM DTT, 0.75 mg Ub, 60 ng E1 and 300 ng E2. Reactions were incubated at 371C for 45 min, terminated by adding of 30 ml 2 Â SDS loading buffer, boiled for 4 min, and resolved by SDS-PAGE followed by autoradiography to visualize the ubiquitination ladders. Substrate p53 was co-immunoprecipitated with CUL7 from p53-deficient H1299 cells co-transfected with a transcriptional inactive mutant p53R273H. p53 ubiquitination was determined by immunoblotting using a monoclonal p53 antibody (DO1).
For the in vivo p53 ubiquitination assay, U2OS cells were transfected with plasmids expressing various proteins and HAubiquitin as indicated in each figure. Total amount of plasmid DNA in each transfection was adjusted to total 2.4 mg with pcDNA3 empty vector when needed. At 20 h after transfection, cells were treated with proteasome inhibitor MG132 (25 mM) for 4 h. Cells were then collected, pelleted by centrifugation, and lysed in 200 ml of pre-boiled SDS-lysis buffer (50 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 1% SDS, 1 mM DTT), and further boiled for an additional 10 min. Lysates were clarified by centrifugation at 14 000 r.p.m. on a microcentrifuge for 10 min. Supernatant was diluted 10-fold with 0.5% NP-40 buffer and immunoprecipitated with antip53 antibody (3.6 mg). Immunoprecipitates were washed three times and resolved on a 7.5-15% gradient SDS-PAGE, followed by immunoblotting with anti-HA antibody (1 mg/ ml) to detect HA-tagged ubiquitin.
Retroviral production and transduction
Plates (10 cm) of 293T cells were transfected using the calcium phosphate method with 7 mg total DNA (3 mg pHIT-myc3-CUL7, pHIT-myc3-CUL7
DN680
, pHIT-myc3-CUL7 D389À404 or pHIT-GFP for transfection and infection efficiency determination, plus 2 mg pCI-VSV and 2 mg pCI-PGZ). Cells were incubated at 371C in DMEM supplemented with 10% FBS, 1% Penn/Strep and 25 mM chloroquine for 18 h. The medium was replaced with DMEM supplemented with 2% FBS and incubated for 24 h at 321C. Viral supernatant was then collected and filtered using a 0.45 mM syringe filter, supplemented up to 10% with fresh FBS, and 10 mg/ml polybrene. Six-well plates of U2OS or H1299 cells were incubated with 2 ml per well of the viral media for 24 h at 371C. Cell infection efficiency was determined by GFP, and if needed, cells were subsequently infected to increase infection efficiency.
Growth curves U2OS and H1299 cells and their derivative lines expressing stably either the wild-type or mutant CUL7 were plated onto twenty 60 mm plates at a density of either 4 Â 10 4 ( Figure 8b ) or 2 Â 10 5 (Figure 8c ) per plate. Each day cells from two plates were trypsinized and counted to determine the amount of cells per plate. From each plate two separate samples were taken, and from each one of these samples two separate counts were made. Each plate and cell type was averaged from the eight individual counts to determine the cell number per cell line for that day. Relative proliferation for each day was determined by dividing the average daily cell number by the original amount of cells per plate as determined on day 1.
Luciferase reporter assays
Cells were transfected in triplicate with various combinations of plasmids expressing different proteins as indicated and total transfected DNA was normalized to 1 mg total cDNA per each 10 mm plate. Luciferase reporter assays were carried out following the Dual Luciferase reporter assay protocol (Promega, Madison, WI, USA). Briefly, cells were lysed with 500 ml of PLB (Passive Lysis Buffer) for 15 min at room temperature. Lysates were collected and frozen at À801C to ensure complete lysis. Lysates were thawed, cleared by centrifugation, and 20 ml were added to 100 ml of luciferase assay reagent. Firefly luciferase activity was assayed and recorded on a luminometer. In total, 100 ml of Stop and Glo reagent was added to each sample to determine Renilla luciferase activity. Individual samples were normalized and luciferase activity was determined.
UV irradiation and FACS analysis U2OS and H1299 cells and their derivatives stably expressing CUL7 were treated with 40 J/m 2 of UV radiation using a Stratagene UV Stratalinker 2400. Irradiated cells were fixed with 100% ethanol to a final concentration of 75%. Fixed cells were washed with PBS and permeabilized with 0.1% Triton X-100, 0.1% mg/ml RNase in PBS for 30 min at 371C. Cells were stained using propidium iodide (1 mg/ml) for 18 h at 41C and sorted using a Becton Dickinson FACScan and data analysed using Summit software.
